Multiple Myeloma Hub

57 Episodes

1. What is the rationale for treating early RRRM with targeted therapies?

   Published: 5/2/2025
2. What is the impact of belantamab mafodotin on QoL in patients with MM?

   Published: 4/30/2025
3. What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma?

   Published: 4/29/2025
4. Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma

   Published: 8/13/2024
5. Integrating cilta-cel into earlier lines of therapy: Rationale and latest data from CARTITUDE-2 and CARTITUDE-4

   Published: 8/9/2024
6. Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma

   Published: 8/9/2024
7. Teclistamab: real-world safety and efficacy

   Published: 8/8/2024
8. Infections associated with bispecific antibodies

   Published: 7/16/2024
9. CAR T-cell therapies in clinical practice

   Published: 7/16/2024
10. How to select maintenance therapies post-ASCT for patients with high-risk MM?

    Published: 9/18/2023
11. Should risk-adapted MM treatment be informed by age or frailty status?

    Published: 9/12/2023
12. How is the immune reconstitution in patients who stop therapy after achieving MRD negativity?

    Published: 2/9/2023
13. What are the main discrepancies between MM treating centers in Brazil?

    Published: 2/6/2023
14. What are the initial data of dara-CyBorD in patients with extramedullary disease?

    Published: 2/3/2023
15. Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?

    Published: 10/2/2022
16. Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM

    Published: 8/5/2022
17. The role of consolidation after autologous stem cell transplantation

    Published: 8/5/2022
18. What are the pros and cons of bispecific antibodies for multiple myeloma?

    Published: 7/25/2022
19. Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM

    Published: 4/21/2022
20. Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?

    Published: 1/14/2022